Clinical trial

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

NCT04193527

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention DaTSCAN™ Ioflupane (123I) Injection Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-06-28

PhasePHASE3

Conditions

Parkinsonian Syndromeunresolved

Parkinson Disease(PD)unresolved

Multiple System Atrophy (MSA)unresolved

Progressive Supranuclear Palsy (PSP)unresolved

Essential Tremorverified · MONDO: essential tremor

Interventions

DaTSCAN™ Ioflupane (123I) InjectionDRUG

Sponsors & collaborators

GE Healthcarelead sponsor

PPD Development, LPcollaborator

Mapped research locations

BeijingChina2 ShanghaiChina1 NanjingJiangsu, China1 TianjinChina1 SuzhouJiangsu, China1 GuangdongGuangzhou, China1 BeijingChaoyang District, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04193527 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.